Primary nonresponse to anti-cd20 therapy in gastrointestinal posttransplant lymphoproliferative disorder.
作者信息
Gökçe Selim, Süoğlu Ozlem Durmaz, Sökücü Semra, Gün Feryal, Emiroğlu Haldun, Celik Alaaddin, Doğan Oner, Cevikbaş Uğur
机构信息
Department of Pediatric Gastroenterology, Hepatology and Nutrition, Istanbul University Istanbul School of Medicine, Istanbul, Turkey.
出版信息
J Pediatr Gastroenterol Nutr. 2006 Mar;42(3):316-20. doi: 10.1097/01.mpg.0000189333.85268.b9.
Abstract
摘要
相似文献
1
Primary nonresponse to anti-cd20 therapy in gastrointestinal posttransplant lymphoproliferative disorder.胃肠道移植后淋巴组织增生性疾病对抗CD20治疗的原发性无反应。
J Pediatr Gastroenterol Nutr. 2006 Mar;42(3):316-20. doi: 10.1097/01.mpg.0000189333.85268.b9.
2
Monoclonal antibody therapy for posttransplant lymphoproliferative disorders.移植后淋巴细胞增生性疾病的单克隆抗体治疗
Liver Transpl. 2000 Sep;6(5):657-8. doi: 10.1002/lt.500060520.
3
Post-transplant lymphoproliferative disorder treated with rituximab: case report.利妥昔单抗治疗移植后淋巴细胞增生性疾病：病例报告
Chin Med J (Engl). 2007 May 5;120(9):841-3.
4
Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation?肝移植后成人单用抗CD20单克隆抗体利妥昔单抗治疗移植后淋巴细胞增生性疾病：实体器官移植后移植后淋巴细胞增生性疾病患者治疗的新药？
Transplantation. 2000 Feb 15;69(3):430-2. doi: 10.1097/00007890-200002150-00021.
5
High-intensity chemotherapy and rituximab for the treatment of posttransplant lymphoproliferative disorder.高强度化疗联合利妥昔单抗治疗移植后淋巴细胞增殖性疾病。
Am J Clin Oncol. 2006 Apr;29(2):211-2. doi: 10.1097/01.coc.0000162640.27701.9f.
6
PTLD treatment: reducing the chemotherapy burden through addition of rituximab.PTLD治疗：通过添加利妥昔单抗减轻化疗负担
Pediatr Transplant. 2010 Feb;14(1):10-1. doi: 10.1111/j.1399-3046.2009.01289.x.
7
Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation.肝移植后用于治疗移植后淋巴增殖性疾病的利妥昔单抗治疗相关的肠穿孔。
Cancer Chemother Pharmacol. 2009 Sep;64(4):857-60. doi: 10.1007/s00280-009-1062-1. Epub 2009 Jul 9.
8
Rituximab with peripheral blood stem cell transplantation in CD20 lymphoproliferative disorders.利妥昔单抗联合外周血干细胞移植治疗CD20淋巴细胞增殖性疾病。
Haematologica. 2001 Oct;86(10):1104-5.
9
AntiCD20 monoclonal antibody-based radioimmunotherapy of relapsed chemoresistant aggressive post-transplantation B-lymphoproliferative disorder in heart-transplant recipient.基于抗CD20单克隆抗体的放射性免疫疗法治疗心脏移植受者复发的化疗耐药性侵袭性移植后B淋巴细胞增殖性疾病。
Lancet Oncol. 2005 Aug;6(8):629-31. doi: 10.1016/S1470-2045(05)70286-2.
10
Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.移植后淋巴细胞增殖性疾病患者的管理：利妥昔单抗的作用
Transpl Int. 2006 Apr;19(4):259-69. doi: 10.1111/j.1432-2277.2006.00284.x.
引用本文的文献
1
Treatment with rituximab in benign and malignant hematologic disorders in children.利妥昔单抗在儿童良性和恶性血液系统疾病中的治疗应用。
J Pediatr. 2007 Apr;150(4):338-44, 344.e1. doi: 10.1016/j.jpeds.2006.12.038.
Zotero 插件